CRISPR Therapeutics’ (CRSP) “Neutral” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report published on Thursday morning, Benzinga reports.

Other research analysts have also recently issued research reports about the company. Rodman & Renshaw started coverage on CRISPR Therapeutics in a research note on Friday, August 2nd. They set a buy rating and a $90.00 target price for the company. Citigroup decreased their price target on CRISPR Therapeutics from $89.00 to $84.00 and set a buy rating for the company in a research report on Thursday, May 23rd. Chardan Capital decreased their price target on CRISPR Therapeutics from $112.00 to $94.00 and set a buy rating for the company in a research report on Tuesday. Wells Fargo & Company decreased their price target on CRISPR Therapeutics from $70.00 to $65.00 and set an equal weight rating for the company in a research report on Thursday, May 9th. Finally, Needham & Company LLC decreased their price target on CRISPR Therapeutics from $88.00 to $84.00 and set a buy rating for the company in a research report on Tuesday. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Hold and a consensus target price of $74.00.

CRISPR Therapeutics Trading Down 1.8 %

CRSP stock traded down $0.85 during trading hours on Thursday, hitting $47.01. 998,453 shares of the stock traded hands, compared to its average volume of 1,596,176. The stock has a 50-day simple moving average of $56.72 and a 200 day simple moving average of $62.88. CRISPR Therapeutics has a one year low of $37.55 and a one year high of $91.10. The company has a market cap of $3.99 billion, a P/E ratio of -17.28 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The company had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. During the same period in the prior year, the company earned ($0.98) earnings per share. The firm’s quarterly revenue was down 99.3% on a year-over-year basis. Analysts forecast that CRISPR Therapeutics will post -5.52 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CRSP. Capital International Investors boosted its stake in CRISPR Therapeutics by 27.8% in the first quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares in the last quarter. SR One Capital Management LP bought a new stake in shares of CRISPR Therapeutics during the first quarter worth $71,496,000. Norges Bank bought a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $38,661,000. Avoro Capital Advisors LLC bought a new stake in shares of CRISPR Therapeutics during the first quarter worth $28,599,000. Finally, Vestmark Advisory Solutions Inc. bought a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $10,848,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.